SAN DIEGO, April 6 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. today announced the pricing of a public offering of 3,500,000 shares of its common stock. The offering is expected to close on or about April 9, 2010, subject to customary closing conditions. In addition, Ardea Biosciences has granted the underwriters a 30-day option to purchase up to an additional 525,000 shares to cover overallotments, if any.
A registration statement relating to the shares has been filed with, and declared effective by, the Securities and Exchange Commission. A final prospectus supplement relating to the offering will be filed with the Securities and Exchange Commission. Copies of the final prospectus supplement and related prospectus, when available, may be obtained from Jefferies & Company, Inc., Attention: Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022 or at (888) 449-2342. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, the shares in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
(Logo: http://www.newscom.com/cgi-bin/prnh/20091104/ARDEALOGO)
CONTACT: Ardea, John Beck of Ardea Biosciences, Inc., +1-858-652-6523,
jbeck@ardeabio.com; or media, Heidi Chokeir, Ph.D. of Russo Partners, LLC,
+1-619-528-2217, heidi.chokeir@russopartnersllc.com, for Ardea Biosciences,
Inc.
Web site: http://www.ardeabiosciences.com/
